文献速递药物不良反应与药物警戒

人轮状病毒疫苗Rotarix上市后15年肠套叠安全性监测数据综述

Review of Over 15 Years Postmarketing Safety Surveillance Spontaneous Data for the Human Rotavirus Vaccine (Rotarix) on Intussusception.
PubMed 文献 · Drug Saf · 2022-01-11

该综述回顾了GSK全球安全性数据库中2004至2020年Rotarix接种后肠套叠(IS)的自发报告病例,并进行了观察值与预期值(O/E)分析。结果显示IS报告以男性为主,主要发生在接种后7天内尤其是第一剂后,与已知轮状病毒疫苗安全性特征一致。早期识别和及时就医可改善IS预后,应告知家长注意婴儿异常行为。

要点

  • IS自发报告以男性为主,主要发生在接种后7天内,尤其是第一剂后。
  • 确诊IS病例中常见症状为呕吐、便血和哭闹,多数需住院或手术干预。
  • 应告知家长接种后婴儿出现异常行为时立即就医,早期管理预后良好。

核心结论

  • Rotarix接种后IS自发报告特征与已知轮状病毒疫苗安全性特征一致,即接种后短暂增加IS发生率,主要在第一剂后7天内。
  • 早期IS管理预后优于延迟管理,医疗专业人员应告知家长婴儿接种后出现异常行为时立即就医。

研究设计与样本

  • 回顾性分析GSK全球安全性数据库2004至2020年所有Rotarix接种后IS自发报告病例。
  • 对归因于IS的不良事件进行观察值与预期值(O/E)分析,并按地区(欧洲/美国/日本)和剂量分层。

主要发现

  • 确诊IS病例(Brighton Collaboration Working Group 1级)中,接种后30天内最常见事件为呕吐(55.8%)、便血(47.2%)和哭闹(21.1%)。
  • 862例确诊报告中557例需住院,557例住院病例中294例需手术干预。
  • 男性占IS患者的56.3%。

临床怎么用

  • 临床药师应告知家长Rotarix接种后婴儿出现异常行为(如哭闹、呕吐、便血)时立即就医。
  • 关注接种后7天内尤其第一剂后的IS风险,早期识别和及时转诊可改善预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Rotavirus (RV) is the most common cause of acute gastroenteritis in children <5 years of age worldwide, and vaccination reduces the disease burden. Evidence from postmarketing surveillance studies suggested an increased risk of intussusception (IS) in infants post-RV vaccination. An overall positive benefit-risk balance for the human RV vaccine (HRV) Rotarix (GlaxoSmithKline [GSK], Belgium) has been established and recent findings indicate an indirect effect of reduced IS over the long term. OBJECTIVE: The aim of this study was to discuss spontaneous data from the GSK worldwide safety database on IS post-Rotarix administration. METHODS: The database was reviewed for all spontaneous IS cases from 2004 to 2020. Additionally, an observed versus expected (O/E) analysis was done for adverse events attributed to IS. Data were reviewed as overall worldwide and stratified by region (Europe/USA/Japan) and dose. RESULTS: A male predominance of IS patients was observed, consistent with earlier reports. The most frequently reported events in confirmed IS cases (Brighton Collaboration Working Group [BCWG] level 1) with time to onset ≤ 30 days post-vaccination were vomiting (55.8%), haematochezia (47.2%), and crying (21.1%). The observations from the IS spontaneous cases review and results of the O/E analysis are consistent with the known IS safety profile of RV vaccines: a transient increased incidence of IS post-vaccination (primarily in Europe/Japan/worldwide), mostly within 7 days postdose 1. CONCLUSION: Since the outcomes of early IS management are favourable over delayed management, healthcare professionals should inform parents about the importance of seeking immediate medical advice in case of unusual behaviour of the vaccinated infant. GSK continues to monitor the IS risk post-Rotarix administration through routine pharmacovigilance activities. Rotavirus (RV) is the most common cause of acute gastroenteritis and a major cause of death in young children worldwide. Vaccination has been instrumental in reducing the impact of RV disease. Real-world evidence suggests an increased risk of intussusception (an infrequent type of bowel obstruction) in infants following RV vaccination. We reviewed IS cases reported spontaneously worldwide in children following a two-dose vaccination with the human RV vaccine (Rotarix, GlaxoSmithKline [GSK]) since its launch in 2004. We observed that (1) IS occurred more frequently 7 days after the first dose and, to a lesser extent, after the second dose; (2) boys were more frequently affected than girls (56.3%); (3) of 862 confirmed reported cases, 557 required hospitalisation; and (4) surgical intervention was required for 294 of 557 hospitalised cases. We used statistical analysis to assess whether the number of cases observed would be higher or lower than the natural occurrence of IS (irrespective of vaccination). These results were in line with the known RV vaccine safety profile. It is important to constantly monitor the real-world safety profile of RV vaccines in the postmarketing setting. Since the outcomes of early management of IS are favourable compared with delayed management, healthcare professionals should inform parents to seek immediate medical advice if they observe unusual behaviour in their vaccinated child. In conclusion, our analyses on data of a large patient pool for this rare event reinforce the favourable safety profile of human RV vaccine and the benefits of vaccination in young children.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Singh T, Delannois F, Haguinet F, et al. Review of Over 15 Years Postmarketing Safety Surveillance Spontaneous Data for the Human Rotavirus Vaccine (Rotarix) on Intussusception. Drug Saf. 2022. PMID: 35015268. doi:10.1007/s40264-021-01141-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。